HC Wainwright Issues Positive Forecast for GALT Earnings

Galectin Therapeutics Inc. (NASDAQ:GALT) – Investment analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for shares of Galectin Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per share of ($0.19) for the quarter, up from their previous estimate of ($0.21). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($1.06) EPS.

Separately, StockNews.com lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, December 30th.

Galectin Therapeutics Price Performance

Galectin Therapeutics stock opened at $1.27 on Monday. Galectin Therapeutics has a 12-month low of $0.73 and a 12-month high of $4.27. The company has a market capitalization of $80.24 million, a price-to-earnings ratio of -1.74 and a beta of 0.79. The firm’s fifty day moving average price is $1.46 and its 200 day moving average price is $1.90.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03).

Hedge Funds Weigh In On Galectin Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. acquired a new stake in Galectin Therapeutics in the fourth quarter valued at $26,000. Inspire Advisors LLC increased its position in shares of Galectin Therapeutics by 86.3% in the 4th quarter. Inspire Advisors LLC now owns 21,095 shares of the company’s stock worth $27,000 after purchasing an additional 9,772 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of Galectin Therapeutics in the 4th quarter valued at about $29,000. Two Sigma Securities LLC bought a new position in shares of Galectin Therapeutics during the fourth quarter worth about $37,000. Finally, Bank of America Corp DE grew its stake in Galectin Therapeutics by 101.4% in the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock worth $49,000 after purchasing an additional 19,316 shares in the last quarter. 11.68% of the stock is currently owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.